Jan 16 (Reuters) – Biopharmaceutical company Agomab Therapeutics filed for an initial public offering in the United States on Friday.
IPOs are likely to gain momentum in 2026 as anticipated interest rate cuts bolster investor appetite for new issues, encouraging late-stage drugmakers to test public markets.
J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen are underwriters for the offering.
Belgium-based Agomab Therapeutics will list on the Nasdaq under the symbol “AGMB”
(Reporting by Pritam Biswas in Bengaluru; Editing by Anil D’Silva)
